faron pharmaceuticals oyj shares rose tuesday after it said topline data from its phase 12 trial of its bexmarilimab cancer treatment returned positive results shares at 0826 gmt were up 018 pence or 84 at 238 pence the finnish pharmaceutical company said the new data together with recent scientific advisory board recommendations and pharmacokinetic modeling will allow it to file the end of phase 12 package with the us food and drug administration in late 2022 the latest progress with the trials was focused on higher dose levels and frequencies to finalize the dose for future study designs the company said bexmarilimab was welltolerated in patients receiving higher dose levels or more frequent administration and induced significant systemic interferon gamma increaseshowing the capacity of the treatment to activate an immune response in cancer patients the median overall survival rate for patients from part 1 and 2 of the trial was 149 months for those treated with bexmarilimab compared to 44 months for those who did not we now have a clear understanding of which patients benefit from bexmarilimab treatment and can identify them using a validated staining antibody which can be widely accessible and adapted to routine practice chief executive markku jalkanen said